EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 28 / No 12 (Décembre 2012) Med Sci (Paris), 28 12 (2012) 1069-1071 References
Free Access
Issue
Med Sci (Paris)
Volume 28, Number 12, Décembre 2012
Page(s) 1069 - 1071
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20122812017
Published online 21 December 2012
  1. Nielsen M, Thomsen JL, Primdahl S, et al. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987 ; 56 : 814–819. [CrossRef] [PubMed] [Google Scholar]
  2. Akslen LA, Naumov GN. Tumor dormancy: from basic mechanisms to clinical practice. Apmis 2008 ; 116 : 545–547. [CrossRef] [PubMed] [Google Scholar]
  3. Quesnel B. «Je te tiens, tu me tiens». Dormance tumorale : un équilibre instable? Med Sci (Paris) 2008 ; 24 : 575–576. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  4. Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991 ; 22 : 339–347. [PubMed] [Google Scholar]
  5. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989 ; 339 : 58–61. [CrossRef] [PubMed] [Google Scholar]
  6. Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol 2009 ; 19 : 329–337. [CrossRef] [PubMed] [Google Scholar]
  7. Folkman J, Kalluri R. Cancer without disease. Nature 2004 ; 427 : 787. [CrossRef] [PubMed] [Google Scholar]
  8. Naumov GN, Bender E, Zurakowski D, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006 ; 98 : 316–325. [CrossRef] [PubMed] [Google Scholar]
  9. Straume O, Shimamura T, Lampa MJ, et al. Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci USA 2012 ; 109 : 8699–8704. [CrossRef] [Google Scholar]
  10. Jego G, Hazoumé A, Seigneuric R, Garrido C. Targeting heat shock proteins in cancer. Cancer Lett 2010, 13 novembre (online). [Google Scholar]
  11. Didelot C, Garrido C. HSP90 mitochondriale : la cible à inactiver dans la thérapie anti-cancéreuse ? Med Sci (Paris) 2008 ; 24 : 363–364. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  12. Garrido C, Collura A, Berthenet K, et al. Mutation d’HSP110 dans les cancers colorectaux : le paradoxe du chaperon qui ne protège plus. Med Sci (Paris) 2012 ; 28 : 9–10. [CrossRef] [EDP Sciences] [Google Scholar]
  13. Baylot V, Andrieu C, Katsogiannou M, et al. OGX-427 inhibits tumor progression, enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis 2011 ; 2 : e221. [CrossRef] [PubMed] [Google Scholar]
  14. Rexer H. First line therapy for local advanced or metastasized urothelial carcinoma: randomized double-blind phase II study to compare gemcitabin and cisplatin in combination with OGX-427 or placebo for advanced transitional cell carcinoma of the bladder (OGX-427 - AB 39/11 of the working group urological oncology. Urologe A 2011 ; 50 : 1617–1618. [CrossRef] [PubMed] [Google Scholar]
  15. Panigrahy D, Edin ML, Lee CR, et al. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest 2012 ; 122 : 178–191. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.